Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2354Neoplasms 1704Prostatic Neoplasms 1192Lung Neoplasms 922Colorectal Neoplasms 884Carcinoma, Non-Small-Cell Lung 866Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 574Multiple Myeloma 551Carcinoma, Hepatocellular 516Brain Neoplasms 515Neoplasm Metastasis 461Head and Neck Neoplasms 457Melanoma 414Ovarian Neoplasms 412Glioblastoma 402Precursor Cell Lymphoblastic Leukemia-Lymphoma 398Stomach Neoplasms 376Uterine Cervical Neoplasms 362Squamous Cell Carcinoma of Head and Neck 362Rectal Neoplasms 342Recurrence 335Sarcoma 324Hematologic Neoplasms 324Colonic Neoplasms 321Lymphoma 320Triple Negative Breast Neoplasms 289Carcinoma, Renal Cell 283Urinary Bladder Neoplasms 281Glioma 280

Interventions

Janus Kinase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immune Checkpoint Inhibitors (ICI)-Related Dermatitis × 1 year × Clear all
NCT06715982 2025-10-28

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Hangzhou Cancer Hospital

Phase 2 Recruiting
35 enrolled

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡